DDInter1729 DDInter1297
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. Niraparib was approved by the European Commission on November 16, 2017 and by Health Canada on June 27, 2019.
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Sulindac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Methotrexate
Methotrexate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Sulindac {u} (Compound) palliates {v} (Disease) osteoarthritis
osteoarthritis {u} (Disease) is palliated by {v} (Compound) Ketoprofen
Ketoprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Sulindac {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nonsteroidal Anti-inflammatory Compounds {u} (Pharmacologic Class) includes {v} (Compound) Oxaprozin
Oxaprozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Sulindac {u} (Compound) causes {v} (Side Effect) Alopecia
Alopecia {u} (Side Effect) is caused by {v} (Compound) Carbamazepine
Carbamazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Sulindac {u} (Compound) binds {v} (Gene) PPARD
PPARD {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Treprostinil
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Sulindac {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Niraparib
Sulindac {u} (Compound) causes {v} (Side Effect) Urine color abnormal
Urine color abnormal {u} (Side Effect) is caused by {v} (Compound) Deferiprone
Deferiprone {u} may lead to a major life threatening interaction when taken with {v} Niraparib
Sulindac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Niraparib
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Sulindac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Methotrexate (Compound) and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Sulindac (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Ketoprofen (Compound) and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Sulindac (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Oxaprozin (Compound) and Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Sulindac (Compound) causes Alopecia (Side Effect) and Alopecia (Side Effect) is caused by Carbamazepine (Compound) and Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Sulindac (Compound) binds PPARD (Gene) and PPARD (Gene) is bound by Treprostinil (Compound) and PPARD (Gene) is upregulated by Treprostinil (Compound) and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Sulindac (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Niraparib
Sulindac (Compound) causes Urine color abnormal (Side Effect) and Urine color abnormal (Side Effect) is caused by Deferiprone (Compound) and Deferiprone may lead to a major life threatening interaction when taken with Niraparib
Sulindac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Niraparib